Victory Capital Management Inc. Purchases 55,322 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Victory Capital Management Inc. boosted its position in ADMA Biologics, Inc. (NASDAQ:ADMA) by 192.6% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 84,046 shares of the biotechnology company’s stock after acquiring an additional 55,322 shares during the period. Victory Capital Management Inc.’s holdings in ADMA Biologics were worth $940,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in ADMA. EntryPoint Capital LLC purchased a new stake in shares of ADMA Biologics during the first quarter worth about $31,000. Simplicity Wealth LLC bought a new position in ADMA Biologics during the 1st quarter valued at approximately $68,000. Oxford Asset Management LLP purchased a new stake in ADMA Biologics in the 4th quarter worth approximately $83,000. CWM LLC grew its position in shares of ADMA Biologics by 114.2% in the 2nd quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock worth $92,000 after buying an additional 4,367 shares during the last quarter. Finally, Viewpoint Capital Management LLC grew its position in shares of ADMA Biologics by 18.6% in the 1st quarter. Viewpoint Capital Management LLC now owns 15,416 shares of the biotechnology company’s stock worth $102,000 after buying an additional 2,416 shares during the last quarter. Institutional investors own 75.68% of the company’s stock.

ADMA Biologics Trading Up 1.2 %

NASDAQ ADMA opened at $19.98 on Friday. The firm has a market capitalization of $4.63 billion, a PE ratio of -999.00 and a beta of 0.61. The stock’s 50 day moving average is $15.77 and its 200 day moving average is $10.93. ADMA Biologics, Inc. has a twelve month low of $3.06 and a twelve month high of $20.16. The company has a quick ratio of 2.80, a current ratio of 6.87 and a debt-to-equity ratio of 0.74.

ADMA Biologics (NASDAQ:ADMA) last announced its earnings results on Thursday, August 8th. The biotechnology company reported $0.13 EPS for the quarter, beating analysts’ consensus estimates of $0.08 by $0.05. The firm had revenue of $107.20 million for the quarter, compared to analysts’ expectations of $86.44 million. ADMA Biologics had a net margin of 10.53% and a return on equity of 38.79%. The company’s quarterly revenue was up 78.4% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.02) EPS. Research analysts forecast that ADMA Biologics, Inc. will post 0.49 earnings per share for the current fiscal year.

Analyst Ratings Changes

ADMA has been the subject of a number of recent analyst reports. HC Wainwright upped their target price on ADMA Biologics from $10.00 to $18.00 and gave the company a “buy” rating in a report on Monday, August 12th. Cantor Fitzgerald restated an “overweight” rating and issued a $20.00 price objective on shares of ADMA Biologics in a report on Friday. Finally, Mizuho lifted their target price on shares of ADMA Biologics from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Thursday, June 20th. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, ADMA Biologics currently has a consensus rating of “Buy” and an average price target of $15.50.

Insiders Place Their Bets

In other news, Director Lawrence P. Guiheen sold 9,000 shares of ADMA Biologics stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $18.47, for a total transaction of $166,230.00. Following the completion of the transaction, the director now directly owns 153,941 shares in the company, valued at $2,843,290.27. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Lawrence P. Guiheen sold 9,000 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $18.47, for a total transaction of $166,230.00. Following the completion of the transaction, the director now owns 153,941 shares of the company’s stock, valued at approximately $2,843,290.27. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Young Kwon sold 60,000 shares of the business’s stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $18.26, for a total value of $1,095,600.00. Following the completion of the sale, the director now directly owns 241,441 shares in the company, valued at $4,408,712.66. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 466,900 shares of company stock worth $8,224,121. 3.70% of the stock is currently owned by company insiders.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.